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The sex hormone system in carriers of BRCA1/2 mutations: 
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Christopher K Edlund, Susan J Ramus, Simon A Gayther, Louis Dubeau, Evangelia Ourania Fourkala, Alexey Zaikin, Usha Menon, Ian J Jacobs
Summary
Background Penetrance for breast cancer, ovarian cancer, or both in carriers of BRCA1/BRCA2 mutations is 
disproportionately high. Sex hormone dysregulation and altered end-organ hormone sensitivity might explain this 
organ-speciﬁ c penetrance. We sought to identify diﬀ erences in hormone regulation between carriers of BRCA1/2 and 
women who are negative for BRCA1/2 mutations.
Methods We assessed endometrial thickness for each menstrual cycle day (as an index of hormone regulation) in 
393 scans from 228 women in the UK Familial Ovarian Cancer Screening Study (UK FOCSS) known to carry either 
mutation and 1573 scans from 754 women known to be negative for the mutations. To quantify diﬀ erences in 
endometrial thickness we focused on days 10–14 and days 21–26, and calculated the area under the curve. We then 
compared serum oestradiol and progesterone titres during these days of the menstrual cycle in the same groups. 
Follicular and luteal oestradiol and progesterone serum titres were grouped into quartiles and odds ratios were 
calculated with logistic regression.
Findings Follicular phase endometrial thickness of carriers of the mutations adjusted for age and day of the menstrual 
cycle was higher (odds ratio [OR] 1·11, 95% CI 1·03–1·20; p=0·0063) and luteal phase endometrial thickness lower 
(0·90, 0·83–0·98; p=0·027) than for women negative for the mutations. Median luteal phase titres of progesterone 
were 121% higher (p=0·00037) in carriers than in women negative for the mutations, and for oestradiol were 33% 
higher (p=0·007)—ie, 59% of carriers had concentrations of serum progesterone that would have been in the top 
quartile of concentrations in the control group (OR 8·0, 95% CI 2·1–52·57; p=0·008).
Interpretation Carriers of BRCA1/BRCA2 mutations are exposed to higher titres of oestradiol and progesterone—
known risk-factors for breast cancer. Higher titres of oestradiol in carriers are compatible with this hormone having a 
role in ovarian carcinogenesis in such women. Our ﬁ ndings could not be explained by diﬀ erential contraceptive pill use.
Funding Eve Appeal, European Union, Cancer Research UK, and US National Institutes of Health.
Introduction
In all inherited cancer syndromes the germline mutation 
is thought to have a so-called local eﬀ ect in an organ that 
is predisposed to the development of cancer, because 
these mutations do not cause cancers in all organs. For 
example, the increased cancer risk in carriers of the 
BRCA1 and BRCA2 mutations is predominantly that of 
breast cancer, ovarian cancer, or both.1 These mutations 
are thought to cause cancer via a defect in DNA damage 
response or in the DNA repair pathway.2 However, this 
defect does not explain the organ-speciﬁ c cancer 
penetrance. That removal of both ovaries and Fallopian 
tubes reduces not only the risk of ovarian but also breast 
cancer3 implicates a systemic dysregulation of hormone 
production in carriers of the mutation, which aﬀ ects both 
the Müllerian epithelium, as the cell of origin for ovarian 
cancer,4 and breast epithelium. Evidence from preclinical 
models suggests that both hormone production and 
hormone sensitivity of end organs is altered in carriers of 
the BRCA1 mutation. Studies in animals5–7 showed that 
mice carrying a Brca1 mutation in the steroid-hormone-
producing granulosa cells had a longer pro-oestrus phase, 
corresponding with the oestrogen-dominant follicular 
phase of the human menstrual cycle. Furthermore, 
serum oestradiol titres in mutant mice were higher than 
those of wild-type mice when both groups were stimulated 
with exogenous gonadotropins. Also, the insulin-like 
growth factor system has a fundamental role in 
endometrial biology, acting via autocrine and paracrine 
mechanisms.8 There are strong interactions between the 
insulin-like growth factor and BRCA1 signalling 
pathways, which also involve oestrogen signalling;9 
hence, it is possible that the endometrium of carriers of 
the BRCA1 mutation has altered sensitivity to hormones.
Cyclical change in oestradiol and progesterone titres 
alters endometrial thickness and menstrual bleeding in 
premenopausal women. We postulate that both endo-
metrial thickness as a functional index of hormonal 
activity in a target organ that undergoes cyclic changes, 
and serum ovarian steroid hormone titres at particular 
stages of the menstrual cycle, would diﬀ er between 
carriers of the BRCA1/BRCA2 mutations and women 
who are known to have no BRCA1/BRCA2 mutations.
The UK Familial Ovarian Cancer Screening Study 
(UK FOCSS; registered with Current Controlled Trials, 
number ISRCTN32794457)10 has accrued suﬃ  cient 
Lancet Oncol 2013; 14: 1126–32
Published Online
October 17, 2013
http://dx.doi.org/10.1016/
S1470-2045(13)70448-0
See Comment page 1151
Copyright © Widschwendter et al. 
Open Access article distributed 
under the terms of CC BY
*Contributed equally
Department of Women’s 
Cancer, UCL EGA Institute for 
Women’s Health 
(Prof M Widschwendter MD, 
A N Rosenthal PhD, 
S Philpott MSc, I Rizzuto MD, 
L Fraser BSc, J Hayward MSc, 
E O Fourkala PhD, 
Prof A Zaikin PhD, 
Prof U Menon MD, 
Prof I J Jacobs MD), and 
Department of Mathematics 
(Prof A Zaikin PhD), University 
College London, London, UK; 
Barts Cancer Institute, Barts and 
the London School of Medicine 
and Dentistry, London, UK 
(A N Rosenthal); Department of 
Preventive Medicine 
(M P Intermaggio MSc, 
C K Edlund MSc, S J Ramus PhD, 
Prof S A Gayther PhD), and 
Department of Pathology 
(Prof L Dubeau PhD), Keck School 
of Medicine, USC/Norris 
Comprehensive Cancer Center, 
University of Southern 
California, Los Angeles, CA, USA; 
and Faculty of Medical and 
Human Sciences, University of 
Manchester and Manchester 
Academic Health Science Centre, 
Manchester, UK (Prof I J Jacobs)
Correspondence to:
Prof Martin Widschwendter, 
Department of Women’s Cancer, 
UCL EGA Institute for Women´s 
Health, University College 
London, London WC1E 6AU, UK
M.Widschwendter@ucl.ac.uk
For more on the UK FOCSS 
see http://www.
instituteforwomenshealth.ucl.
ac.uk/academic_research/
gynaecologicalcancer
Articles
www.thelancet.com/oncology   Vol 14   November 2013 1227
prospective data and samples to allow assessment of our 
hypotheses. Because many women in the study had 
undergone clinical genetic testing for BRCA1/2 
mutations, we had a cohort of women known to carry the 
mutation and a cohort known to be negative for the 
mutation to compare. However, most of the women in 
the study had not undergone clinical genetics testing. 
To establish the mutation status of these women, high-
throughput next generation sequencing provided the 
fastest and most cost-eﬀ ective method of rapidly 
detecting carriers of the mutations, albeit with potentially 
lower sensitivity than clinical testing, which in the UK 
uses a combination of Sanger sequencing (including 
limited Ashkenazi mutation screening where 
appropriate) and multiplex ligation probe ampliﬁ cation.
Methods
Participants
After ethical approval (Eastern MREC 97/5/007), 
UKFOCSS recruited from 44 UK regional centres. 
Between June, 2002, and September, 2010, women older 
than 35 years, at an estimated minimum 10% lifetime 
risk of ovarian cancer based on family history or 
predisposing germline gene mutations (appendix) were 
recruited and screening data and outcomes were 
collected prospectively. So far, about 25% of the study 
population have undergone clinically initiated testing for 
BRCA1 and BRCA2 mutations (either before or after 
recruitment).
After ethical approval (Joint University College London/
University College London Hospital Ethics Committee, 
ref 06/Q0505/102), we selected all premenopausal 
UKFOCSS participants with no previous or subsequent 
history of cancer (to avoid including women on hormonal 
therapy or women with a subclinical cancer, which could 
have triggered an altered hormonal environment and 
which could have confounded our analyses) and no 
intrauterine device.
Procedures
Ovarian cancer screening was done with transvaginal 
sonography to assess ovarian morphology and serum 
CA125 tumour marker measurement. All centres 
scanned study participants and all scans were done by 
sonographers, radiologists, or gynaecologists approved 
by the UK’s National Health Service (NHS), employed by 
the local hospital for gynaecological scanning, and 
subject to local NHS quality control. Initially, CA125 tests 
were done annually, but after 2007 these tests were done 
every 4 months. Samples were taken in EDTA-containing 
tubes at women’s primary care practices and posted to 
our laboratory for aliquoting, CA125 testing, and storage 
at –80°C. Samples were discarded if they reached the 
laboratory more than 56 h after venepuncture or were 
haemolysed. Endometrial thickness and date of last 
menstrual period were routinely recorded during 
sonography. Information on use of oral contraceptive 
pills was collected in a general health questionnaire sent 
to all UK FOCSS participants in 2011, asking whether 
they had used the oral contraceptive pill in each of their 
third, fourth, and ﬁ fth decades.
We assessed UK FOCSS volunteers for germline 
mutations in the coding sequence of BRCA1 and BRCA2 
with the Illumina HiSeq2000 sequencer (San Diego, CA 
USA; appendix). Participants were included if they 
matched our inclusion criteria and had provided a DNA 
sample.
Oestradiol and progesterone were measured with 
automated immunoassays on the Elecsys 2010 analyser 
(Roche Diagnostics GmbH, Mannheim, Germany). The 
measuring range for oestradiol was 18–15 800 pmol/L 
and for progesterone was 0·095–191 nmol/L. Standard 
Westgard rules were applied. Mutation carriers and 
controls were randomly mixed in batches and analysis 
was masked. Single lot numbers of reagent and calibrator 
were used. The oestradiol intra-assay coeﬃ  cient of 
variability (CV) is 1·6–5·7% and interassay CV is 
2·3–6·2%. The progesterone intra-assay CV is 1·5–2·7% 
and interassay CV is 3·7–5·4%.
Statistical analysis
Endometrial thickness for each group was averaged for 
each day of menstrual cycle and smoothed using the 
averaging running window of 5 days. For example, if ﬁ ve 
women had samples from cycle day 10, we ﬁ rst took the 
mean result for these ﬁ ve women. We then took the 
mean of the means for days 8–12 and plotted this as the 
value for day 10. On start and end days of the menstrual 
cycle the dependencies were prolonged—eg, for day 1, 
endometrial thickness was averaged over days 30, 31, 1, 2, 
and 3. To quantify diﬀ erences we focused on days 10–14 
and days 21–26 (because these were the times in the 
cycle when diﬀ erences were most pronounced), and 
calculated the area under the curve (AUC). Diﬀ erences 
in AUC and in distributions represented in boxplots 
were estimated with the Mann-Whitney U test. To 
construct the distributions for AUCs, the endometrial 
thickness values were bootstrapped: for each cycle day 
the thickness value was sampled with replacement, then 
the obtained dependence was averaged using a window 
of 5 days and the AUC was calculated for the obtained 
dependence between days 10–14 and 21–26. The odds 
ratios (ORs) for BRCA status were obtained for 
endometrial thickness, treated as a continuous predictor 
variable, and adjusted in the logistic regression for age 
and the speciﬁ c menstrual cycle day as continuous 
variables.
Follicular and luteal oestradiol and progesterone serum 
titres were grouped into quartiles and ORs were 
calculated with logistic regression. Because endometrial 
thickness, oestradiol, and progesterone data did not 
diﬀ er signiﬁ cantly between carriers of BRCA1 and 
BRCA2 mutations (appendix), we combined the data of 
the mutation carriers to increase statistical power with 
See Online for appendix
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the limited number of samples available. ORs for BRCA 
status were obtained for endometrial thickness, treated 
as a continuous predictor variable, and adjusted for age 
and the speciﬁ c menstrual cycle day. Software R version 
2.11.1 was used for statistics.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
2808 endometrial-thickness measurements and associated 
last menstrual period dates were available from 1460 
eligible women, including 1573 endometrial thickness 
measurements in women negative for both mutations, 
203 in carriers of BCRA1, and 190 in carriers of BRCA2 
(baseline data shown in the appendix). 254 women had 
BRCA testing done during the course of the UK FOCSS 
and 728 women (who had provided DNA) had their BRCA 
status assessed after the trial by next generation sequencing 
(ﬁ gure 1). Information on use of oral contraceptive pills 
during the decade when the transvaginal scan was done 
was available for 1711 (87%) of 1966 endometrial thickness 
measurements and was not signiﬁ cantly diﬀ erent in any 
of the groups assessed (table 1).
409 stored serum samples from cycle days 10–14 and 
days 21–26 were available from known carriers of BRCA1 
(n=38) and BRCA2 (n=32) mutations and negative 
controls (n=339) for oestradiol and progesterone testing.
Figure 2 and table 2 show endometrial thickness in the 
study groups by menstrual cycle day. Endometrial 
thickness was higher in the follicular phase in carriers 
than in controls negative for the mutations, but lower 
than that of controls in the luteal phase. The AUC of 
endometrial thickness in both follicular and luteal phase 
diﬀ ered signiﬁ cantly when comparing carriers of either 
mutation with those who were carriers of neither 
mutation (p<0·0001 for both comparisons) and 
endometrial thickness results did not diﬀ er signiﬁ cantly 
between carriers of the mutations (appendix). In view of 
this statistically similar endometrial thickness pattern in 
carriers of the mutations, we combined these groups, 
and noted clear diﬀ erences between the combined carrier 
group and the group negative for mutations (ﬁ gure 2 and 
table 2). In the follicular phase, the carrier group’s 
endometrial thickness was signiﬁ cantly higher, whereas 
in the luteal phase endometrial thickness was 
signiﬁ cantly lower than that of non-carriers, even after 
using logistic regression analysis and adjusting for age 
and menstrual cycle day. To assess whether a woman’s 
knowledge of her mutation status might aﬀ ect the results 
(eg, by changing her lifestyle in an attempt to minimise 
her cancer risk), we separately analysed the 728 women 
in the next generation sequencing group who did not 
know their mutation status during the trial. The same 
endometrial thickness pattern between mutation carriers 
and non-mutation carriers was noted (appendix). To be 
certain that the endometrial thickness diﬀ erences were 
not due to diﬀ erential oral contraceptive pill use, we 
analysed the 1318 endometrial thickness scans for which 
the women had reported no oral contraceptive pill use in 
the decade the scan was done (table 1). Again, we noted 
the same endometrial thickness patterns as before 
(appendix), with higher follicular phase endometrial 
thickness and lower luteal phase endometrial thickness 
in carriers of the mutations than for women negative for 
the mutations.
BRCA1 and 
BRCA2 
negative
BRCA1 or 
BRCA2 
mutation
p value*
All scans
No contraceptive pill use 1099 (77%) 219 (78%) 0·61
Contraceptive pill use 332 (23%) 61 (22%)
Mutation status known during the trial†
No contraceptive pill use 46 (81%) 191 (79%) 0·73
Contraceptive pill use 11 (19%) 52 (21%)
Mutation status assessed after the trial‡
No contraceptive pill use 1053 (77%) 28 (76%) 0·89
Contraceptive pill use 321 (23%) 9 (24%)
Use of oral contraceptive pills in the same decade as endometrial thickness scan was 
available for 87% of the 1966 endometrial thickness scans done. *From χ² test. 
†Women whose mutation status was established with clinical genetics testing. 
‡Women whose mutation status was established with next generation sequencing. 
Table 1: Proportions of endometrial thickness scans with known 
contraceptive pill use during decade of ultrasound scan
Figure 1: Availability of transvaginal ultrasound scans
Scans from women within the UK Familial Ovarian Cancer Screening Study (UK FOCSS) who had clinically initiated 
BRCA testing before or during the trial (A) or who had BRCA testing by next generation sequencing after the trial 
ﬁ nished (B). In the UK, clinically initiated testing is done primarily on women with stronger family histories and 
aﬀ ected living relatives. Therefore the only diﬀ erence between B and A is that the former would have had a lower 
a-priori risk of being mutation carriers—this explains the lower prevalence of mutations recorded in B versus A. 
However, there was no diﬀ erence in ultrasound methods, data collection, sample collection, or storage for these 
women, so this is not a source of bias. Consequently no statistical adjustment was deemed necessary. 
ET=endometrial thickness.
2808 scans from 1460 UK FOCSS volunteers for whom 
            ET available and who do not have cancer
BRCA1 and BRCA2 testing done
1966 scans in 982 volunteers
            1573 scans in 754 negative for both mutations
              203 scans in 116 carrying the BRCA1 mutation
              190 scans in 112 carrying the BRCA2 mutation
Mutation status known during trial (A)
429 scans in 254 volunteers
           86 scans in 51 negative for both mutations
         177 scans in 104 carrying the BRCA1 mutation
        166 scans in 99 carrying the BRCA2 mutation
Mutation status assessed after trial (B)
1537 scans in 728 volunteers
           1487 scans in 703 negative for both mutations
                26 scans in 12 carrying the BRCA1 mutation
                24 scans in 13 carrying the BRCA2 mutation
Articles
www.thelancet.com/oncology   Vol 14   November 2013 1229
The diﬀ erences in endometrial thickness between 
carriers and those negative for the mutations could be a 
consequence of diﬀ erent hormonal sensitivity of the 
target tissue (ie, the endometrium) in carriers of the 
mutations, triggered by diﬀ erent titres of the steroid 
hormones known to regulate endometrial biology, or a 
combination of the two. Although it is diﬃ  cult to assess 
hormonal sensitivity directly, to assess the triggering 
threshold we analysed oestradiol and progesterone in 
stored serum samples from all premenopausal carriers 
of the mutations who provided samples between days 
10–14 (follicular phase) and 21–26 (luteal phase; n=59, 
mean age 40·6 years, 70 samples), and all women 
negative for the mutations (n=283, mean age 43·5 years, 
339 samples). Again, there were no diﬀ erences between 
carriers of either mutation (appendix). Oestradiol titres 
did not diﬀ er signiﬁ cantly between the carrier and 
mutation-negative groups during days 10–14 (appendix). 
Progesterone titres during day 10–14 were not measured 
in all women because pilot data in 38 carriers and 
44 controls showed such low titres (median 1·27 nmol/L 
in carriers and controls) that no signiﬁ cant diﬀ erences 
would become apparent on testing all available samples. 
Median luteal phase titres of progesterone were 121% 
higher (p=0·00034) in carriers than in women negative 
for the mutations, and oestradiol titres were 33% higher 
(p=0·007)—ie, 59% of carriers had concentrations of 
serum progesterone that would have been in the top 
quartile of concentrations in the control group (OR 8·0, 
95% CI 2·1–52·57; p=0·008; appendix, ﬁ gure 3).
Discussion
Our ﬁ ndings show clear diﬀ erences in cyclical 
endometrial thickness in carriers of BRCA1/2 mutations 
compared with wild-type controls. We have also shown 
congruent changes in sex-hormone titres, which are one 
of the probable explanations for this diﬀ erence. Our 
cohort of well matched premenopausal carriers and 
controls with combined endometrial thickness infor-
mation, and serum samples with known menstrual cycle 
data, was ideal for testing the hypothesis that the organ-
speciﬁ c cancer penetrance in carriers is due to hormonal 
dysregulation. To our knowledge, the UK FOCSS 
population is the largest cohort for whom this 
information is available (panel).
Our ﬁ ndings of high luteal phase progesterone titres in 
carriers of BRCA mutations, associated with decreased 
endometrial thickness, are in complete concordance with 
each other, and might relate to a defect in steroid-hormone 
regulation in carriers that results in an end-organ eﬀ ect. 
We speculate that the high luteal phase oestradiol we 
recorded in carriers triggers increased expression of 
progesterone receptors,11 thus potentiating any possible 
mutagenic eﬀ ect of the higher luteal progesterone. Our 
ﬁ ndings support those from studies in mice carrying a 
Brca1 mutation in ovarian granulosa cells.6,7 Although data 
on endogenous premenopausal progesterone exposure 
and cancer risk is less extensive and less conclusive,12 
postmenopausal exogenous progesterone exposure is a 
well established risk factor for breast cancer.11,13–15 We were 
recently part of a collaborative report suggesting that 
progestogens cause breast cancer by inducing expression 
of the receptor activator of NF-κB ligand (RANKL), and 
that deleting the receptor for this ligand delays the onset 
of progestogen-driven breast cancers.16 There is already an 
Figure 2: Endometrial thickness as a function of the menstrual cycle
(A) Endometrial thickness calculated from 1573 transvaginal ultrasound scans from 754 women negative for both 
mutations, 203 scans from 116 carriers of the BRCA1 mutation, and 190 scans from 112 carriers of the BRCA2 
mutation. (B) Endometrial thickness in 754 women negative for both mutations (1573 scans) and the combined 
228 women who were carriers of either mutation (393 scans). OR=odds ratio. *Adjusted for menstrual cycle day 
and age.
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antibody against RANKL (denosumab), which is used at 
present for the treatment of osteoporosis. Our ﬁ ndings 
might therefore provide the basis for trials of this antibody 
as a chemopreventive agent for BRCA1/2-triggered breast 
cancer. In conjunction with data that show the potential of 
a progesterone antagonist to prevent BRCA1-mediated 
mammary tumorigenesis in mice,17 our ﬁ ndings provide 
an additional rationale for treatment that interferes with 
progesterone signalling to prevent breast cancer in 
carriers of BRCA1/BRCA2 mutations. One such 
compound (the progesterone receptor modulator, 
ulipristal acetate) has been used successfully for treatment 
of uterine ﬁ broids, with fewer side-eﬀ ects than agonists of 
luteinising-hormone-releasing hormone.18,19 We speculate 
that such drugs could be used as chemoprophylaxis for 
women at high risk of breast cancer.
The recorded higher follicular phase endometrial 
thickness in carriers of the BRCA1/2 mutations was not 
associated with any diﬀ erences in follicular phase titres 
of oestradiol and progesterone between carriers and 
controls. We speculate that the higher follicular phase 
endometrial thickness in carriers might be a consequence 
of altered endometrial sensitivity to steroid hormones. 
Evidence on endometrial cancer penetrance in carriers20 
suggested that excess endometrial cancer risk was 
explained by use of tamoxifen. This ﬁ nding suggests that 
the endometrium of carriers might be more sensitive to 
oestrogen-receptor agonists.
Oestrogen replacement usage21 and obesity (a hyper-
oestrogenic state)22 are established epidemiological risk 
factors for ovarian cancer, implicating hormonal 
dysregulation in its pathogenesis. Our data, suggesting 
higher oestradiol titres in the luteal phase of the 
menstrual cycle in women who are carriers of the 
BRCA1/2 mutations compared with women negative for 
the mutations supports this hypothesis. We speculate 
that the higher titres of progesterone with concordant 
reduced endometrial thickness recorded in the luteal 
phase in the carrier group compared with the control 
group might explain why the penetrance for the third 
hormonally triggered cancer—namely endometrial 
cancer—in carriers is much lower than that for ovarian 
and breast cancer; it is well recognised that progestogens 
suppress endometrial proliferation,23 resulting in a 
thinner endometrial thickness and lower lifetime risk of 
endometrial cancer.24
Panel: Research in context
Systematic review
We searched PubMed for studies on BRCA mutation and 
alterations in the female premenopausal reproductive 
hormone system published in English between Sept 1, 1993, 
and Feb 28, 2013. We used the search terms (“BRCA1” or 
“BRCA2”) and (“endocrine” or “hormones” or “endometrium” 
or “menstrual”). We established that studies in animals 
showed aberrant hormonal regulation upon loss of BRCA1 in 
granulosa cells and that premenopausal surgical resection of 
the ovaries in women carrying the BRCA1 or BRCA2 mutation 
led to a substantial reduction in the risk of breast cancer.3 
Systemic endocrine eﬀ ects of BRCA1 or BRCA2 mutations 
have not previously been assessed in humans.
Interpretation
Our ﬁ ndings suggest that BRCA1/2 germline mutations are 
driving carcinogenesis only in part via altered molecular 
pathways (eg, those involved in DNA repair) in the organ at 
risk, and that BRCA1/2-associated changes in the endocrine 
system are additional factors. These insights could act as a 
major impetus for novel chemoprevention trials using 
strategies that can exploit the hormonal dysregulation in 
carriers of BRCA1/2 mutations. Potential agents for these 
trials include selective oestrogen or progesterone receptor 
modulators, and the anti-RANKL (receptor activator of NF-κB 
ligand) antibody denosumab (currently used for osteoporosis 
treatment, but known to block the downstream carcinogenic 
eﬀ ects of progestogens).
Figure 3: Serum progesterone and oestradiol analysis during luteal phase of 
the menstrual cycle
Boxplots with horizontal line show 25%, 50%, and 75% quartiles. Error bars 
show 95% CIs.
0
20
40
60
0
200
600
1000
80
400
800
O
es
tr
ad
io
l (
pm
ol
/L
)
Pr
og
es
te
ro
ne
 (n
m
ol
/L
)
Negative BRCA1/2
mutation
Negative BRCA1/2
mutation
p=0·00034p=0·0074
Area under curve p value
Days 10–14 
of cycle
Days 21–26 
of cycle
n AUC n AUC
Separate BRCA analysis <0·0001
BRCA1 mutation 40 32 31 43
BRCA2 mutation 42 32 32 41
BRCA1/2 negative 308 28 274 45
Combined BRCA analysis <0·0001
BRCA1/2 mutated 82 32 63 41
BRCA1/2 negative 308 28 274 45
AUC=area under curve. n=number of volunteers.
Table 2: Endometrial thickness as a function of menstrual cycle in 
women by BRCA1 and BRCA2 mutation status
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Our study has certain limitations. Although we 
excluded women with a levonorgestrel-releasing 
intrauterine device, we had limited information on use of 
oral contraceptive pills. We only recorded use of the pill 
in the same decade as the endometrial scan. However, 
these data were available on 87% of the women for whom 
we had endometrial thickness data. Based on these data, 
oral contraceptive use during the same decade as the 
ultrasound scan did not diﬀ er between carriers and 
controls. Furthermore, in view of the age of the cohort 
(all were >35 years) and their known increased risk of 
breast cancer, it is probable the proportion using the 
contraceptive pill at the time of sample donation would 
have been even lower than the data above. Most 
importantly, excluding women with unreported pill use 
and those known to have taken the pill in the same 
decade as the scan did not reduce the statistical 
signiﬁ cance of the endometrial thickness diﬀ erences 
between carriers and controls.
The control group could have included participants 
that carry BRCA1/2 mutations who were missed using 
our next generation sequencing mutation-detection 
methods (eg, mutations in regions of low sequence 
coverage or large genomic rearrangements). Although it 
is not possible to estimate the frequency of missed 
mutations, the individuals screened were unaﬀ ected and 
therefore had at most a 50% chance of inheriting a 
germline mutation even if it were present in their family. 
Therefore, the frequency of BRCA1/BRCA2-positive 
individuals in the screen-negative group is probably very 
low. Any mutation carriers in the screen-negative group 
would bias our ﬁ nding towards the null, suggesting that 
our study has underestimated rather than overestimated 
the strength of the recorded eﬀ ects.
We had insuﬃ  cient numbers of scans with last 
menstrual period dates of a cycle length greater than 
28 days to draw any conclusions about whether carriers 
of BRCA1/BRCA2 mutations might have a longer 
menstrual cycle than women negative for the mutations, 
as was evident in the previously described mouse 
model.5–7 If this were the case, then we speculate that 
longer cumulative exposure, and the observed higher 
absolute titres of progesterone and to a lesser extent 
oestradiol, might contribute to the excess breast cancer 
risk of carriers of the mutations.
Our study cannot address whether endometrial 
thickness and hormone titres are respectively a marker 
and eﬀ ector of breast cancer risk within a BRCA1/2-
mutant population. Women with such a mutation have a 
very high (up to 85%) lifetime risk of breast cancer. 
Therefore many women undergo risk-reducing salpingo-
oophorectomy, mastectomy, or both. As a result 
addressing the question as to whether altered endometrial 
thickness and steroid hormone titres in premenopausal 
women are markers for subsequent breast cancer risk or 
not would be diﬃ  cult to do. It would need a substantial 
prospective long-term study of pre menopausal BRCA-
carriers who were unwilling to undergo risk-reducing 
surgery but willing to be followed up for decades. Our 
ﬁ ndings suggest that sex steroids are one of the major 
drivers for development of breast cancer in this 
population.
We deliberately excluded patients who had a previous 
diagnosis of breast or ovarian cancer because they could 
have been on antiendocrine therapy or chemotherapy, 
which would have altered their ovarian function and 
biased our ﬁ ndings. We also excluded the few women 
who developed breast or ovarian cancer subsequent to 
their scan or serum sample donation. It is well known 
that sex steroids are locally produced within invasive but 
also within non-invasive breast carcinoma,25 which might 
not have been clinically apparent at the time of sample 
donation. Furthermore, small subclinical ovarian 
tumours might potentially interfere with normal 
hormone production. Hence we decided a priori not to 
include women with a diagnosis of breast or ovarian 
cancer subsequent to sample donation to avoid any bias 
that would favour the hypothesis of an aberrant endocrine 
system being associated with cancer development in 
high-risk women. It could be argued that by excluding 
cases of subsequent breast cancer, we have diluted the 
breast cancer risk proﬁ le of our study group. However, 
despite this, we have noted hormonal changes that would 
be expected to increase breast cancer risk (ie, raised 
oestradiol and progesterone in carriers vs controls). 
Furthermore, because of the young age of the study 
group (all were premenopausal), most have not yet 
reached the age at which their breast cancer would be 
likely to occur, so most of the excess breast cancer risk of 
the study population has yet to accrue. Excluding the 
small number of women who we know developed breast 
cancer subsequent to sample donation would be likely to 
minimise diﬀ erences between carriers and controls, 
making our ﬁ ndings more compelling.
To improve statistical power, we combined carriers of 
BRCA1 and BRCA2 mutations into a single study group. 
Although we acknowledge that it is possible that there 
are biological diﬀ erences between these groups relevant 
to our investigation, we did not identify statistical 
diﬀ erences between them with respect to endometrial 
thickness or hormone titres (appendix). Furthermore, 
ﬁ gure 2 clearly shows that both groups have a similar 
pattern of higher follicular phase endometrial thickness 
and lower luteal phase endometrial thickness compared 
with women negative for the mutations.
Although we have in eﬀ ect analysed multiple cross-
sectional data rather than longitudinal data, we have still 
identiﬁ ed statistically signiﬁ cant diﬀ erences between 
carriers and controls. Furthermore, longitudinal data 
would need a prospective study of a similar number of 
mutation carriers and controls, requiring daily 
venepuncture and transvaginal sonography. We feel such 
a study would be logistically challenging and recruitment 
for it would be extremely diﬃ  cult.
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The control group was not a random sample from the 
general population, but rather was deliberately selected 
for high familial risk of ovarian cancer (to minimise any 
diﬀ erences between mutation carriers and controls). 
The control group’s results might not therefore be 
representative of the general population. However, their 
shared increased ovarian cancer risk makes them the 
most appropriate control group to compare with carriers 
of BRCA1/BRCA2 mutations.
In conclusion, our ﬁ ndings provide novel insights into 
the high penetrance for breast cancer (via higher 
progesterone and oestrogen titres) and also possibly 
ovarian cancer (via higher oestrogen titres and potentially 
lower titres of anti-Müllerian hormone26) in carriers of 
BRCA1/BRCA2 mutations. Our ﬁ ndings provide a 
rationale for novel cancer prevention strategies in these 
women. They also provide a possible explanation for the 
absence (via higher progesterone titres) of high 
penetrance for endometrial cancer in carriers.
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